Saturday, May 31, 2025

Latest

Medipharm Labs Appoints Former Purdue Pharma Exec As CEO

Medipharm Labs (TSX: LABS) continues to suffer from management turnover. The company today announced that its CEO, Bryan Howcroft, will be stepping down for personal reasons effective immediately. Howcroft was in the role for just six months.

Taking Howcroft’s place within the company is that of David Piddick, whom Medipharm lists as previously serving as a president and CEO of a “Canadian pharmaceutical company.” That pharma company is believed to be Purdue Pharma Canada, whom notably faced numerous lawsuits related to the opioid pandemic which ultimately lead to a bankruptcy filing in the US. Piddick will also serve on the firms board of directors.

Piddick reportedly has over two decades worth of senior leadership experience within the healthcare industry. He currently holds a MBA from Northwestern University.

“In MediPharm, I see one of the very few organizations globally that has the required sophistication to both operate within a stringent Pharma environment, and scale rapidly to capitalize on this growth opportunity. I look forward to contributing my experience in business and corporate development to the team’s current efforts, with a focus on orienting the Company toward both consistent organic growth and accretive M&A activities to drive revenue growth, profitability and value for all stakeholders,” commented Piddick on his appointment.

As part of Piddick’s compensation package, he was issued 14.8 million RSU’s in connection with his appointment, as well as 5.2 million stock options.

Howcroft meanwhile has exited his role from the firm entirely, announcing this morning he will also be vacating his position on the firms board.

Medipharm Labs last traded at $0.145 on the TSX.


Information for this briefing was found via Sedar and MediPharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

2 Responses

Leave a Reply

Video Articles

How To Profit From $3300 Gold? An Inside Look At A Massive 300,000 Oz Project | Martino De Ciccio

We’re At The Start of a Great Silver Boom | Ross McElroy & Andy Bowering – Apollo Silver Corp

Equinox Gold Q1 Earnings: When Everything Goes Wrong

Recommended

ESGold Begins Concentration Tests Ahead Of First Production

Sterling Metals Hits 0.21% Copper Over 482.8 Metres In First Drilling At Soo Copper project

Related News

Medipharm Labs Posts Revenues of $13.9 Million, Net Loss of $3.5 Million For Q2 2020

Medipharm Labs (TSX: LABS) reported further disappointing quarterly results this morning, with revenues of $13.9...

Thursday, August 13, 2020, 09:25:18 AM

Medipharm Labs Applies for Nasdaq Listing

Medipharm Labs (TSX: LABS) announced this morning that it has submitted an application for listing...

Tuesday, November 5, 2019, 09:37:00 AM

Medipharm Labs Receives Price Target Reduction From Canaccord To $1.75

Yesterday, On November 16th, Medipharm Labs (TSX: LABS) reported their third quarter financial results. Reported...

Tuesday, November 17, 2020, 03:37:00 PM

Hexo Has Filed A $35 Million Counterclaim Against Medipharm Labs

It appears that Hexo Corp (TSX: HEXO) (NYSE: HEXO) has filed a counterclaim against Medipharm...

Thursday, June 18, 2020, 11:48:39 AM

Medipharm Labs: Canaccord Drops Target To Just $0.10

On May 16, Medipharm Labs (TSX: LABS) reported its first quarter financial results. The company...

Tuesday, May 24, 2022, 11:37:00 AM